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metastasis arising from the parotid glandTetsuya Yamamotoa,*, Tetsuro Okamotoa, Yukihiro Tatemotob,
Tsuyoshi Kimuraa, Eisaku Uetaa, Tokio OsakiaaDepartment of Oral Oncology, Kochi Medical School, Kohasu, Oko-cho,
Nankoku, Kochi 783-8505, Japan
bDepartment of Oral Surgery, Kochi Municipal Hospital, 1-7-45 Marunouchi, Kochi, Kochi 780-0850, JapanReceived 28 October 2003; accepted 12 January 2004Summary We present a rare case of an ossifying adenocarcinoma originating in the
parotid gland. Of a 52-year-old female with complaints of preauricular swelling, jaw
trismus and mental nerve paralysis. Panoramic radiography and computed tomog-
raphy revealed a tumor in the right preauricular region extending to the mandibular
head and radiopaque miliary shadows in the lungs. Histopathologically, the tumor
revealed characteristics of adenocarcinoma with prominent ossification. The
immunostaining for bone morphogenetic protein-2 and osteopontin suggested that
the ossification was induced by the tumor cells. Despite chemoimmunotherapy with
TS-1 and OK-432 and later with an epidermal growth factor-receptor antagonist,
gefitinib, the original tumor and metastatic pulmonary foci continued to growth and
the patient eventually died about 15 months after the start of therapy.c 2004 Published by Elsevier Ltd.
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A variety of tumors are formed in the salivary
glands and their histopathologic identification is
difficult especially in some types of adenomas and
adenocarcinomas.1;2 Among malignant tumors of
the salivary glands, adenocarcinoma is the third* Corresponding author. Tel.: +81-88-880-2423; fax: +81-88-
880-2424.
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Abbreviations: CT: computed tomography; BMP-2: bone
morphogenic protein-2; EGF-R: epidermal growth factor-recep-
tor; CEA: Carcinoembryogenic antigen; 5-FU: 5-fluorouracil.
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doi:10.1016/j.ooe.2004.01.002most common after mucoepidermoid carcinoma
and adenoid cystic carcinoma.3 There are several
subcategories of adenocarcinoma, most of which
for example, mucous (mucin producing) adeno-
carcinoma and low grade pleomorphic adenocar-
cinoma, are very rare.1;4
Ossification and cartilage formation are occa-
sionally observed in benign pleomorphic adeno-
mas5;6 and in a few pulmonary adenocarcinomas,7;8
although the mechanism of ossification in adeno-
carcinomas has not been explored. Experimentally,
osteomas were generated from an established sal-
ivary gland carcinoma cell line by cultivation of the
cells in the presence of chemicals.9 However,
ossification has not been reported in salivary gland
Ossifying adenocarcinoma originating in the parotid gland 47adenocarcinomas. Recently, we experienced a rare
case of adenocarcinoma arising from the parotid
gland. The adenocarcinoma revealed multiple
miliary metastases to the lungs and the existence
of ossification in the tissue biopsied from the par-
otid gland region. We present this rare tumor and
discuss briefly the ossification and metastasis.Figure 1 Patient’s profile at the first visit. The pre-
auricular region surrounded by arrow-heads is slightly
and diffusely swollen.Case report
History and macroscopic findings
A 52-year old woman experiencing a spontane-
ous dull pain in the perauricular region in February,
2002, visited an otolaryngologist, but could not
obtain an accurate diagnosis. In the middle of
March, paresthesia was induced in the right side
mental nerve-innervated area and she consulted a
brain surgeon but the sensation was not diag-
nosed. Then, the limitation in jaw movement was
accompanied by hypoesthesia and preauricular
pain, and her dentist referred her to our clinic
suspecting temporomandibular joint dysfunction.
The right side preauricular region together with its
surrounding area was diffusely swollen (Fig. 1). The
region was tender to press and a borderless hard
mass was palpable. The opening of her mouth was
reduced to about one fingerbreadth and the prickle
test revealed almost complete numbness of the
mental nerve.
Rentogenographic and computed
tomographic findings
A panoramic X-ray graph showed diffuse bone
resorption of the right side mandibular head and
neck. Computed tomography (CT) demonstrated a
borderless tumor from the subcutaneous area to
around the mandibular head (Fig. 2A). In the bor-
derless shadow, multiple radiopaque particles of
various size were observed. Chest X-ray examina-
tion suggested pulmonary metastasis and CT
clearly revealed multiple radiopaque shadows in
both lungs (Fig. 2B).
Histopathologic findings
The tumor tissue biopsied from the preauricular
region at the first visit revealed characteristics of
adenocarcinoma with ossification (Fig. 3A). The
parotid gland structure was almost completely
destroyed and occupied by proliferating tumor
cells. The tumor consisted of proliferating colum-
nar and a small number of cuboidal cells with asevere atypism. Ossification was prominent in some
areas. The ossificated particles bound with collag-
enous fibers. The columnar and cuboidal tumor
cells were positive for bone morphogenic protein-2
(BMP-2), osteopontin and epidermal growth factor-
receptor (EGF-R) (Fig. 3B and C).
The clinico-pathological findings indicated a
choice of conservative surgey and the patient
underwent chemoimmunotherapy with 5-fluoro-
uracil (5-FU) prodrug TS-1 (Taiho Pharm. Co., Ltd.,
Tokushima, Japan) and a streptococcal prepara-
tion, OK-432 (Chugai Pharm. Co., Ltd., Tokyo,
Japan). From the middle of April to the end of
August, 100 mg/day of TS-1 was administered or-
ally with intermittent short pauses and 5 Klinische
Einheiten/week of OK-432 was injected subder-
mally. With this combined therapy, the progression
of the original site tumor appeared to be largely
suppressed. However, the concentration of car-
cinoembryogenic antigen (CEA) in peripheral blood
serum increased gradually from 48.1 ng/ml before
the treatment to 350 ng/ml after. Periodical CT
examination revealed marked enlargement of the
primary tumor and a severe increase in pulmonary
metastatic foci. To slow tumor growth, an EGF-R
antagonist, gefitinib (Astra Zeneca, London, UK)
Figure 2 CT view of the parotid region before treatment (A). In the slice, a borderless tumor with multiple radi-
opaque shadows is formed from the subcutaneous area to the infratemporal fossa and near the lateral pterigoid
lamina. CT view of the lungs before treatment (B). Multiple fine radiopaque particles are scattered in both lungs.
Figure 3 Histologic view before treatment. Epithelial islands with a few ducts are formed in the stromal tissue. In
the tumor tissue, ossificated tissues are scattered. (A) H–E, ·20. insert: high magnification of the arrow area ·150.
Immunostaining of BMP-2 (B) and osteopontin (C). (A) and (B): ·150.
48 T. Yamamoto et al.was choosen for the secondary therapy. With the
consent of the patient’s husband, 250 mg/day of
gefitinib was administered from September 5 to the
end of October. Despite the administration of
gefitinib, the original and pulmonary tumors grad-
ually enlarged and metastases formed at other
sites. The patient eventually died in June, 2003.Discussion
The tumor in the present case revealed a
somewhat atypical clinical manifestation for a
parotid gland tumor. It invaded deeply the man-
dibular head, and mandibular immobility and
mental nerve paralysis were induced. These find-
ings suggest that the original site of the tumor was
the profound lobe of the parotid gland. There wasa possibility that the pulmonary foci were the
original tumor and the preauricular lesion was
metastatic. However, it is quite unnatural for a
pulmonary adenocarcinoma to metastasize to the
parotid gland without affecting other organs and
cervical lymph nodes. The pulmonary lesions were
too small and too multiple to be the original tumor.
In addition, the lungs are the most common target
of metastasis for oral carcinomas including salivary
gland tumors. From these findings and the patient’s
clinical course, the parotid gland appears to be the
original site of the tumor.
The most prominent finding of the present tumor
is ossification. Ossifying adenocarcinomas have
rarely been observed in the lungs and mammary
glands though some cases have been reported.7;8;10;11
However, ossification in salivary adenocarcinomas
has not yet been reported. It was reported that
osteoid matrix was generated from tumor cells in
Ossifying adenocarcinoma originating in the parotid gland 49ossifying adenocarcinoma.9;12;13 In the present
tumor, the cells were strongly positive for BMP-2
and osteopontion as well as for EGF-R. These pro-
tein expression patterns suggests that ossification
was induced by the tumor cells and not by
the connective tissue cells. It is unclear whether
ossification in adenocarcinomas reflects the dif-
ferentiation or de-differantiation of tumor cells.
We speculated that the ossification was part of the
course of tumor cell differentiation and its induc-
tion slows tumor cell proliferation. We therefore
tried to induce ossification using chemoimmuno-
therapy. For the chemotherapy, we chose TS-1, a
5-FU prodrug which exhibits differentiation-induc-
ing activity in adenocarcinomas and squamous cell
carcinomas.14 However, the attempt did not suc-
ceed. For the differentiation, radiation might be
required.
Recently, a molecule-target therapy has been
developed.15;16 Gefitinib is one of the drugs used
for therapy targeting EGF-R.17;18 A series of studies
found that gefitinib was effective against pulmon-
ary non-small carcinomas,17;19 especially adeno-
carcinomas despite inverse effects such as lethal
pulmonary fibrosis.20 Expecting this effect, we
used gefitinib but did not obtain any clear tumor
growth suppression. Certain factors may regulate
the efficacy of the EGF-R antagonist.
The course of the disease took an unfortunate
turn with rare clinical and histologic manifestations
and this taught us the difficulty in treating adeno-
carcinoma with pulmonary metastasis. For the
improvement of therapy, further detailed study is
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